BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...director of medicinal chemistry at Bristol-Myers Squibb Co. and co-founded Tetraphase and fellow anti-infectives company Vicuron Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Dalvance dalbavancin regulatory update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Aug 4, 2014
Company News

Durata Therapeutics sales and marketing update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | May 26, 2014
Clinical News

Dalvance dalbavancin regulatory update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

Dalvance dalbavancin: Phase IIIb started

...years of market exclusivity, if approved. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Apr 7, 2014
Clinical News

Dalvance dalbavancin regulatory update

...cSSTI) caused by susceptible Gram-positive microorganisms. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Feb 17, 2014
Clinical News

Dalbavancin regulatory update

...of market exclusivity, if approved. The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Jan 6, 2014
Clinical News

Dalbavancin regulatory update

...see BioCentury, Nov. 12, 2012). The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

Dalbavancin regulatory update

...in 1H15. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Nov 27, 2013
Company News

Priority Review for Durata's dalbavancin

...year end. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
Items per page:
1 - 10 of 311
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...director of medicinal chemistry at Bristol-Myers Squibb Co. and co-founded Tetraphase and fellow anti-infectives company Vicuron Pharmaceuticals Inc....
BioCentury | Aug 11, 2014
Clinical News

Dalvance dalbavancin regulatory update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Aug 4, 2014
Company News

Durata Therapeutics sales and marketing update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | May 26, 2014
Clinical News

Dalvance dalbavancin regulatory update

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

Dalvance dalbavancin: Phase IIIb started

...years of market exclusivity, if approved. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Apr 7, 2014
Clinical News

Dalvance dalbavancin regulatory update

...cSSTI) caused by susceptible Gram-positive microorganisms. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Feb 17, 2014
Clinical News

Dalbavancin regulatory update

...of market exclusivity, if approved. The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Jan 6, 2014
Clinical News

Dalbavancin regulatory update

...see BioCentury, Nov. 12, 2012). The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Clinical News

Dalbavancin regulatory update

...in 1H15. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
BioCentury | Nov 27, 2013
Company News

Priority Review for Durata's dalbavancin

...year end. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....
Items per page:
1 - 10 of 311